|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TADA2B |
Gene summary for TADA2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TADA2B | Gene ID | 93624 |
| Gene name | transcriptional adaptor 2B | |
| Gene Alias | ADA2(beta) | |
| Cytomap | 4p16.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q86TJ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 93624 | TADA2B | HCC1_Meng | Human | Liver | HCC | 1.40e-09 | -4.92e-03 | 0.0246 |
| 93624 | TADA2B | HCC2_Meng | Human | Liver | HCC | 2.96e-09 | 5.08e-02 | 0.0107 |
| 93624 | TADA2B | HCC1 | Human | Liver | HCC | 5.07e-13 | 2.43e+00 | 0.5336 |
| 93624 | TADA2B | HCC2 | Human | Liver | HCC | 2.55e-19 | 2.66e+00 | 0.5341 |
| 93624 | TADA2B | HCC5 | Human | Liver | HCC | 2.66e-14 | 1.44e+00 | 0.4932 |
| 93624 | TADA2B | S028 | Human | Liver | HCC | 1.97e-02 | 1.98e-01 | 0.2503 |
| 93624 | TADA2B | S029 | Human | Liver | HCC | 1.62e-03 | 2.67e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| GO:00183942 | Liver | HCC | peptidyl-lysine acetylation | 116/7958 | 169/18723 | 5.11e-12 | 2.23e-10 | 116 |
| GO:00064752 | Liver | HCC | internal protein amino acid acetylation | 107/7958 | 160/18723 | 3.77e-10 | 1.23e-08 | 107 |
| GO:00183932 | Liver | HCC | internal peptidyl-lysine acetylation | 105/7958 | 158/18723 | 9.48e-10 | 2.90e-08 | 105 |
| GO:00165732 | Liver | HCC | histone acetylation | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:003105621 | Liver | HCC | regulation of histone modification | 99/7958 | 152/18723 | 1.40e-08 | 3.40e-07 | 99 |
| GO:0031058 | Liver | HCC | positive regulation of histone modification | 58/7958 | 92/18723 | 5.55e-05 | 5.21e-04 | 58 |
| GO:20007561 | Liver | HCC | regulation of peptidyl-lysine acetylation | 41/7958 | 63/18723 | 2.47e-04 | 1.84e-03 | 41 |
| GO:19019831 | Liver | HCC | regulation of protein acetylation | 48/7958 | 77/18723 | 3.49e-04 | 2.43e-03 | 48 |
| GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
| GO:00350651 | Liver | HCC | regulation of histone acetylation | 32/7958 | 54/18723 | 9.59e-03 | 3.62e-02 | 32 |
| GO:1901985 | Liver | HCC | positive regulation of protein acetylation | 27/7958 | 45/18723 | 1.35e-02 | 4.80e-02 | 27 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TADA2B | SNV | Missense_Mutation | c.886C>G | p.Arg296Gly | p.R296G | Q86TJ2 | protein_coding | deleterious(0.02) | benign(0.312) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TADA2B | insertion | Frame_Shift_Ins | novel | c.699_700insTATGACCAGGATGCCGAGACGCTCATCA | p.Gly234TyrfsTer48 | p.G234Yfs*48 | Q86TJ2 | protein_coding | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TADA2B | insertion | In_Frame_Ins | novel | c.876_877insTGC | p.Gln292_Arg293insCys | p.Q292_R293insC | Q86TJ2 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TADA2B | insertion | Frame_Shift_Ins | novel | c.878_879insTGGACTTGGCCTGGTCTCACACCCT | p.Tyr294GlyfsTer29 | p.Y294Gfs*29 | Q86TJ2 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TADA2B | insertion | Nonsense_Mutation | novel | c.1070_1071insCCCCAAGAGGTGATGGAGCATTACGTGAGCATGTACATCCACGG | p.Leu358ProfsTer4 | p.L358Pfs*4 | Q86TJ2 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| TADA2B | deletion | In_Frame_Del | c.731_742delNNNNNNNNNNNN | p.Lys245_Ile248del | p.K245_I248del | Q86TJ2 | protein_coding | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |||
| TADA2B | SNV | Missense_Mutation | novel | c.505C>A | p.Leu169Met | p.L169M | Q86TJ2 | protein_coding | tolerated(0.17) | possibly_damaging(0.854) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TADA2B | SNV | Missense_Mutation | c.199N>A | p.Glu67Lys | p.E67K | Q86TJ2 | protein_coding | tolerated(0.77) | benign(0.01) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TADA2B | SNV | Missense_Mutation | c.246N>G | p.Ile82Met | p.I82M | Q86TJ2 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| TADA2B | SNV | Missense_Mutation | c.892N>A | p.Gly298Arg | p.G298R | Q86TJ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |